Discovery and Horizontal Follow-up of an Autoantibody Signature in Human Prostate Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2015 Feb 13

PMID 25675522

Citations 29

Authors

Paul J Mintz

Anna Cecilia Rietz

Marina Cardo-Vila

Michael G Ozawa

Eleonora Dondossola

Kim-Anh Do

Jeri Kim

Patricia Troncoso

Christopher J Logothetis

Richard L Sidman

Renata Pasqualini

Wadih Arap

Affiliations

Soon will be listed here.

Abstract

In response to an urgent need for improved diagnostic and predictive serum biomarkers for management of metastatic prostate cancer, we used phage display fingerprinting to analyze sequentially acquired serum samples from a patient with advancing prostate cancer. We identified a peptide ligand, CTFAGSSC, demonstrating an increased recovery frequency over time. Serum antibody reactivity to this peptide epitope increased in the index patient, in parallel with development of deteriorating symptoms. The antigen mimicking the peptide epitope was identified as alpha-2-Heremans-Schmid glycoprotein, also known as fetuin-A. Metastatic prostate cancer cell lines and bone metastasis samples displayed robust fetuin-A expression, and we demonstrated serum immune reactivity to fetuin-A with concomitant development of metastatic castrate-resistant disease in a large cohort of prostate cancer patients. Whereas fetuin-A is an established tumor antigen in several types of cancer, including breast cancer, glioblastoma, and pancreas cancer, this report is to our knowledge the first study implicating fetuin-A in prostate cancer and indicating that autoantibodies specific for fetuin-A show utility as a prognostic indicator for prostate cancer patients prone to progress to metastatic disease.

Citing Articles

The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.

Odiase P, Ma J, Ranganathan S, Ogunkua O, Turner W, Marshall D Int J Mol Sci. 2024; 25(23).

PMID: 39684629 PMC: 11641224. DOI: 10.3390/ijms252312918.

Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.

Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R Front Immunol. 2024; 15:1455602.

PMID: 39234247 PMC: 11371560. DOI: 10.3389/fimmu.2024.1455602.

Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.

Jayakrishnan R, Schafer C, Tan S Am J Clin Exp Urol. 2023; 11(2):79-102.

PMID: 37168942 PMC: 10165224.

Serum fetuin-A and RANKL levels in patients with early stage breast cancer.

Afsar C, Aral H, Can O, Can T, Karacetin D, Ali N J Med Biochem. 2023; 42(2):249-257.

PMID: 36987423 PMC: 10040193. DOI: 10.5937/jomb0-37386.

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.

Lou N, Zheng C, Wang Y, Liang C, Tan Q, Luo R Cancer Immunol Immunother. 2022; 72(1):235-247.

PMID: 35831618 PMC: 10991865. DOI: 10.1007/s00262-022-03242-0.

References

Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M . Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem. 1999; 45(8 Pt 1):1240-7. View

Bradley S, Oravecz-Wilson K, Bougeard G, Mizukami I, Li L, Munaco A . Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 2005; 65(10):4126-33. DOI: 10.1158/0008-5472.CAN-04-4658. View

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

Liu R, Wang X, Chen G, Dalerba P, Gurney A, Hoey T . The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007; 356(3):217-26. DOI: 10.1056/NEJMoa063994. View

Jia H, Ye Q, Qin L, Budhu A, Forgues M, Chen Y . Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007; 13(4):1133-9. DOI: 10.1158/1078-0432.CCR-06-1025. View

Szweras M, Liu D, Partridge E, Pawling J, Sukhu B, Clokie C . alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem. 2002; 277(22):19991-7. DOI: 10.1074/jbc.M112234200. View

Schover L, Fouladi R, Warneke C, Neese L, Klein E, Zippe C . The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002; 95(11):2397-407. DOI: 10.1002/cncr.10970. View

Scanlan M, Gure A, Jungbluth A, Old L, Chen Y . Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002; 188:22-32. DOI: 10.1034/j.1600-065x.2002.18803.x. View

Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad K, Sheldon J . Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008; 54(4):713-22. DOI: 10.1373/clinchem.2007.096792. View

10.

Rubin M . Targeted therapy of cancer: new roles for pathologists--prostate cancer. Mod Pathol. 2008; 21 Suppl 2:S44-55. DOI: 10.1038/modpathol.2008.11. View

11.

Xie C, Kim H, Haw J, Kalbasi A, Gardner B, Li G . A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011; 9:43. PMC: 3102624. DOI: 10.1186/1479-5876-9-43. View

12.

Zhang R, Pan X, Huang Z, Weber G, Zhang G . Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One. 2011; 6(8):e23831. PMC: 3166084. DOI: 10.1371/journal.pone.0023831. View

13.

Madrid F, Maroun M . Serologic laboratory findings in malignancy. Rheum Dis Clin North Am. 2011; 37(4):507-25. PMC: 3867234. DOI: 10.1016/j.rdc.2011.09.006. View

14.

Tilli T, Thuler L, Matos A, Coutinho-Camillo C, Soares F, Da Silva E . Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol. 2011; 92(1):13-9. DOI: 10.1016/j.yexmp.2011.09.014. View

15.

Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J . Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer. 2011; 131(4):911-23. DOI: 10.1002/ijc.26462. View

16.

Seto J, Busse B, Gupta H, Schafer C, Krauss S, Dunlop J . Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-A knockout mice. PLoS One. 2012; 7(10):e47338. PMC: 3473050. DOI: 10.1371/journal.pone.0047338. View

17.

Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L . Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein. Pancreatology. 2013; 13(3):290-7. DOI: 10.1016/j.pan.2013.03.010. View

18.

Ammirante M, Shalapour S, Kang Y, Jamieson C, Karin M . Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A. 2014; 111(41):14776-81. PMC: 4205637. DOI: 10.1073/pnas.1416498111. View

19.

Milne G, Dai Q, Roberts 2nd L . The isoprostanes--25 years later. Biochim Biophys Acta. 2014; 1851(4):433-45. PMC: 5404383. DOI: 10.1016/j.bbalip.2014.10.007. View

20.

Chen G, Wang X, Yu J, Varambally S, Yu J, Thomas D . Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res. 2007; 67(7):3461-7. DOI: 10.1158/0008-5472.CAN-06-4475. View